Kyverna Therapeutics, Inc.

What they do

Kyverna is developing miv-cel (a CAR T-cell therapy) for autoimmune diseases, focusing on stiff person syndrome (SPS), generalized myasthenia gravis (gMG), and progressive multiple sclerosis (PMS). The company has no commercial products and no revenue from product sales; it is currently conducting clinical trials and preparing regulatory submissions.

Revenue drivers

• No product revenue — Kyverna has no approved products and has never generated revenue from product sales; all operations are funded by cash reserves and financing.
• Miv-cel franchise — All pipeline value is tied to miv-cel, a single CAR T-cell therapy being developed for SPS, gMG, and PMS; no other product candidates are disclosed.
• Intellectual property and partnerships — The company has ongoing license agreements and collaborations, including with academic institutions, but no disclosed commercial partnerships generating revenue.

Recent performance

For Q2 2026, Kyverna reported cash, cash equivalents, and marketable securities of $199.4 million. As of June 30, 2026, total assets were $219.8 million, with cash and equivalents of $31.8 million and long-term debt of $24.9 million. The company reported net losses of $60.4 million (2023), $127.5 million (2024), and $161.3 million (2025), with operating cash flow of -$52.4 million, -$114.3 million, and -$153.7 million in those years. No revenue was reported in any period.

Strategy

Kyverna is advancing a rolling BLA submission for miv-cel in SPS, targeting completion in Q4 2026, with plans to seek priority review and a potential launch in 2027. The company is enrolling its Phase 3 KYSA-6 trial in gMG, expecting completion by mid-2027, and is expanding its PMS strategy following FDA RMAT designation for non-active secondary progressive multiple sclerosis. Management has hired commercial leadership and is building rare disease launch capabilities. The company says it has an operating runway into 2028.

Risks

• No approved products and losses — Kyverna has no products approved, no product revenue, and expects continued net losses for the foreseeable future.
• Dependence on miv-cel — The entire business depends on the success of miv-cel; any failure to complete trials or obtain approval would materially harm the company.
• Need for additional capital — The company may require substantial additional funding to continue operations, and if not available, it may need to delay or reduce development programs.
• Regulatory and development risks — Miv-cel is in clinical trials; regulatory approval is uncertain, and trials may fail to demonstrate safety or efficacy.

Outlook

Kyverna plans to complete the rolling BLA submission for miv-cel in SPS in Q4 2026 and expects KYSA-8 12-month topline data in Q3 2026. The company expects to complete enrollment in the KYSA-6 Phase 3 gMG trial by mid-2027 and will share longer-term Phase 2 follow-up data in Q3 2026. Management reiterates an operating runway into 2028 and expects to provide a PMS development strategy update by early 2027.